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Simple Summary: Melanoma is clinicopathologically a heterogeneous disease with rising incidence.
Metastatic disease is associated with poor outcomes, and immunotherapy was first approved in
2011 for its treatment. In our analysis of a large national database, we describe the epidemiology,
clinical presentation, and survival outcomes of cutaneous, ocular, and mucosal melanoma in recent
years. Metastatic cutaneous melanoma had better survival than both metastatic ocular and mucosal
melanoma. We found higher odds of metastatic disease at diagnosis amongst African Americans
compared to Caucasians. Additionally, for metastatic cases, we noted 25% lower mortality in
those treated at an academic facility compared to community cancer programs and a 20% realworld survival benefit following approval of immunotherapy. This real-world survival benefit was
definitely seen in Caucasians and those with cutaneous or mucosal melanoma. Further investigation
is needed to confirm this benefit in African Americans and ocular melanoma.
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Abstract: Background: The incidence of invasive melanoma is rising, and approval for the first
immune checkpoint inhibitor (ICI) to treat metastatic melanoma occurred in 2011. We aim to
describe the epidemiology and outcomes in recent years, sociodemographic factors associated with
the presence of metastasis at diagnosis, and the real-world impact of ICI approval on survival
based on melanoma subtype and race. Methods: This is a retrospective analysis of the National
Cancer Database (NCDB) from the years 2004–2015. The primary outcome was the overall survival of
metastatic melanoma by subtype. Secondary outcomes included sociodemographic factors associated
with the presence of metastasis at diagnosis and the impact of treatment facility type and ICI approval
on the survival of metastatic melanoma. Results: Of the 419,773 invasive melanoma cases, 93.80%
were cutaneous, and 4.92% were metastatic at presentation. The odds of presenting with metastatic
disease were higher in African Americans (AA) compared to Caucasians (OR 2.37; 95% CI 2.11–2.66,
p < 0.001). Treatment of metastatic melanoma at an academic/research facility was associated with
lower mortality versus community cancer programs (OR 0.75, 95 % CI 0.69–0.81, p-value < 0.001).
Improvement in survival of metastatic melanoma was noted for Caucasians after the introduction of
ICI (adjusted HR 0.80, 95% CI 0.78–0.83, p < 0.001); however, this was not statistically significant for
AA (adjusted HR 0.80, 95% CI 0.62–1.02, p-value = 0.073) or ocular cases (HR 1.03, 95% CI 0.81–1.31,
p-value = 0.797). Conclusion: Real-world data suggest a 20% improvement in survival of metastatic
melanoma since the introduction of ICI. The disproportionately high odds of metastatic disease
at presentation in AA patients with melanoma suggest the need for a better understanding of the
disease and improvement in care delivery.

Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
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1. Introduction
Melanoma is the fifth most common cancer in the US [1]. A recent Surveillance,
Epidemiology, and End Results (SEER) combined database analysis from 2001 to 2015
demonstrated a steady increase in cases of invasive melanoma between 2001 and 2015 [2].
Melanoma is broadly classified into two categories, cutaneous and noncutaneous. While
noncutaneous melanoma has a lower incidence, it is characterized by a much higher proportion of patients presenting with invasive or metastatic disease compared to cutaneous
melanoma. Of 82,943 cases of melanoma with a known primary site, reported to the
National Cancer Data Base (NCDB) in the United States for 1985–1994, only 5.5% were
ocular, and 1.3% occurred at mucosal sites [3]. According to a report based on data from the
North American Association of Central Cancer Registries, only 6691 cases of noncutaneous
melanoma (4885 ocular and 1806 mucosal) were diagnosed among 851 million person-years
at risk between 1996 and 2000 [4]. The rarity of noncutaneous melanoma is the most likely
explanation for the paucity of large descriptive studies in this area. We, therefore, leveraged
the NCDB, which contains 70% of all newly diagnosed cancers in the US, and included
cases diagnosed within the two last decades to perform such an analysis. Melanoma is
denoted by immunogenic biology and has, thus, been the focus of research, clinical trial developments, and breakthroughs utilizing immune checkpoint inhibitors (ICIs). This led to
Food and Drug Administration (FDA) approval of ipilimumab (Yervoy), an anti-cytotoxic T
lymphocyte associated protein-4 (anti-CTLA4) antibody, in 2011 for the treatment of newly
diagnosed or previously treated unresectable/metastatic melanoma. This was followed by
the approval of programmed cell death protein-1 (PD-1) inhibitors, nivolumab (Opdivo)
and pembrolizumab (Keytruda), in 2014 for the treatment of unresectable or metastatic
melanoma. Since these FDA approvals, the National Comprehensive Cancer Network
(NCCN) has recommended the use of ICIs for unresectable/metastatic melanoma treatment,
solidifying them as a standard of care. This includes the treatment of metastatic ocular
and mucosal melanomas, done in accordance with guidelines for cutaneous metastatic
melanoma [5]. There is a paucity of survival data concerning noncutaneous metastatic
melanoma, both before and after the introduction of these novel agents.
In our study, we carry out an in-depth descriptive analysis of the epidemiology,
prevalence, and outcomes of cutaneous, ocular, and mucosal melanoma in the United States,
using a large cohort of patients from the NCDB, with data collected from 2004 to 2015. We
evaluate the association between socioeconomic–demographic factors and the presence of
metastatic disease at diagnosis. We also investigate the impact of treatment facility type
on mortality of metastatic melanoma and compare survival of patients diagnosed with
metastatic melanoma and its subtypes before and after the introduction of ipilimumab
in 2011, the first ICI approved for this indication. In addition, using real-world data, we
attempt to assess the impact of socioeconomic factors, including levels of education and
household income, type of insurance coverage, and race, on the survival benefit following
the approval of ICIs for treatment of metastatic melanoma.
2. Methods
2.1. Data Source
This is a retrospective cohort study using hospital registry data collected between 2004
and 2015 within the National Cancer Database (NCDB). The NCDB is jointly sponsored
by the Commission on Cancer of the American College of Surgeons and the American
Cancer Society and includes cancer cases from more than 1500 commission-accredited
cancer programs [6]. This study was determined to be exempt from full review by the
Henry Ford Health System Institutional Review Board (IRB number: 13,331).
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2.2. Study Population
The study selection criteria are outlined in Figure 1. We included patients ≥18 years
of age who had the appropriate morphology and disease stage using International Classification of Diseases for Oncology 3rd Edition (ICD-O-3) codes for invasive melanoma.
Based on ICD-O-3 topographical codes of primary sites for skin and noncutaneous sites, we
divided the study population into two groups, cutaneous and noncutaneous melanoma [7].
Only patients with a known primary site were included in this study. The noncutaneous
group was further divided into two major subtypes, ocular and mucosal. The cohort of
mucosal melanoma patients included those with invasive melanoma arising in the head
and neck, anorectum, gastrointestinal tract (excluding anorectum) and genitourinary system. These categories were generated using conventionally used categorization schema
in the literature [3,8–11]. All the ICD-O-3 codes used for the purpose of this study and
their descriptions are provided in Table S1. The NCDB Participant User File (PUF) dictionary was used to define variables for the study [12]. American Joint Committee on
Cancer (AJCC) staging was applied to melanomas of the skin only, given the absence of
a standardized staging system for most of the noncutaneous melanoma subtypes. We,
therefore, collected data regarding lymph node status (positive/negative/unknown status
or not examined) and the presence or absence of distant metastasis at the time of diagnosis
to define the extent of disease. The main histologic groupings, representing cutaneous
melanomas, were nodular, lentigo maligna, superficial spreading, acral lentiginous, and
melanoma, not otherwise specified (NOS). The remaining histologies were categorized as
“other”. In addition to tumor site, histology, and extent of disease, data regarding patient
characteristics, including age, gender, race, and chronic comorbid conditions quantified by
Charlson/Deyo score, were collected. Socioeconomic demographics, including insurance
status, median family income by zip code, proportion of residents without a high school
diploma by zip code, and geographical region of United States, were collected. Treatment
and care accessibility-related factors, including structural characteristics of the facility
delivering the care (i.e., community cancer program, academic/research cancer program,
or integrated network cancer program) and treatment modality received (systemic therapy,
radiotherapy, or surgery), were also collected.
2.3. Outcomes and Statistical Analysis
We conducted a descriptive analysis of the baseline clinicopathologic features of the
included patients and used the chi-square test to compare the characteristics of patients
by subgroup.
2.4. Primary Outcome
Overall survival (OS) of metastatic melanoma by subtype: OS was defined as the number of months from the patient’s date of diagnosis to either their date of death or when they
were lost to follow-up, as the NCDB does not collect cancer-specific survival. The cumulative OS rates and median OS were estimated using Kaplan–Meier analysis for each of the
cutaneous, ocular, and mucosal melanoma subgroups.
2.5. Secondary Outcomes
Association of socioeconomic and demographic factors with the presence of metastatic
disease at diagnosis: Multivariate logistic regression was used to analyze factors including
age, sex, race, comorbidity burden, degree of education, income level, insured status,
geographical location, and treatment facility type.
Impact of treatment facility type on survival in metastatic melanoma: This was analyzed using multivariate logistic regression to distinguish potential differences between
the outcome of treatment at institutions identified as academic, community, and integrated
network cancer programs.
Impact of the introduction of ICIs on survival in metastatic melanoma: Using the year
of approval of ipilimumab as a landmark (2011), we compared the survival of metastatic
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melanoma cases diagnosed between 2004 and 2010 against those diagnosed between 2011
and 2015. We also analyzed the impact of race on this outcome.
All p-values were two-sided. p-values less than 0.05 were considered statistically
significant. Statistical analysis was performed using Stata/IC version 15.1 (StataCorp LP,
College Station, TX, USA).

Figure 1. Case schema for invasive melanoma subtypes for years 2004–2015 National Cancer Data Base (NCDB).

3. Results
3.1. Baseline Characteristics
Of the 11,970,999 adult cancer patients in the database, 552,989 (4.62%) had melanoma,
of which 419,773 (75.91%) had invasive melanoma. Only patients with invasive disease
were included in this study. As shown in Figure 1, cases of invasive melanoma could
be subdivided into cutaneous melanoma (93.80%) and noncutaneous melanoma (6.20%).
The noncutaneous cohort was further divided into ocular (68.06%) and mucosal (28.57%)
subtypes. Table 1 shows the baseline characteristics of these cohorts. The main histologic groupings of cutaneous melanoma included superficial spreading (29.61%), nodular
(9.31%), lentigo maligna (5.10%), and acral lentiginous (1.31%). The remaining groups were
melanoma, NOS (50.31%), and other (4.36%). The majority cases (67.38%) of cutaneous
melanoma were Stage 1 at diagnosis (Table S2a). Table 2 shows the mortality and extent of
disease based on the histological subtypes of cutaneous melanoma, while Table 3 analyzes
the differences in key characteristics of cutaneous melanoma based on race. Amongst
cases of ocular melanoma, 90.28% (n = 15,992) originated in the uvea, while 4.95% (n = 877)
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originated in the conjunctiva. Amongst cases of mucosal melanoma, 43.78% (n = 3255)
originated in the genitourinary (GU) tract, 34.82% (n = 2589) in the head and neck (H&N)
region, 18.17% (n = 1351) in the anorectal part of the gastrointestinal tract (GIT) and 3.23%
(n = 240) in the GIT, excluding anorectum. Table 4 compares the baseline characteristics
of the mucosal subtypes. The most common subtypes of H&N melanoma included the
nasal/paranasal (72.85%, n = 1886) and oral (21.55%, n = 558). Amongst the GU melanoma
cases, the most common type included female GU (90.48%, n = 2945), followed by male
GU (5.04%, n = 164) and urinary tract (4.49%, n = 146) melanoma.
Table 1. Baseline characteristics of all invasive melanoma subtypes (National Cancer Database; NCDB 2004–2015).
Invasive Melanoma (All Cases)

Cutaneous Melanoma
n = 393,750 (%)

Ocular
Melanoma
n = 17,713 (%)

Mucosal Melanoma
n = 7435 (%)

Chi-Squared p-Value

Females

166,288 (42.23)

8491 (47.94)

5237 (70.44)

<0.001

17,498 (4.44)
202,128 (51.33)
174,124 (44.22)

423 (2.39)
9153 (51.67)
8137 (45.94)

126 (1.69)
2697 (36.27)
4612 (62.03)

<0.001

383,462 (97.39)
2382 (0.60)

16,861 (95.19)
178 (1.00)

6681 (89.86)
380 (5.11)

0
1
2
≥3

338,934 (86.08)
43,252 (10.98)
8529 (2.17)
3035 (0.77)

14,698 (82.98)
2428 (13.71)
426 (2.41)
161 (0.91)

5959 (80.15)
1132 (15.23)
249 (3.35)
95 (1.28)

Positive Lymph Nodes identified

45,177 (11.64)

18 (0.11)

1211 (16.76)

<0.001

Age

≤30 Years
31 to 64 Years
≥65 Years
Race
Caucasian
African American

<0.001

Charlson Deyo score
<0.001

Metastatic disease at diagnosis

19,492 (5.11)

326 (1.90)

873 (12.61)

<0.001

Died

103,211 (26.21)

5388 (30.98)

4947 (66.54)

<0.001

9674 (2.46)
206,840 (52.53)
10,145 (2.58)
167,091(42.44)

600 (3.39)
8486 (47.91)
534 (3.01)
8093 (45.69)

187 (2.52)
2608 (35.08)
274 (3.69)
4366 (58.72)

27,642 (7.05)
69,139 (17.63)
100,822 (25.71)
194,588 (49.62)

1739 (9.86)
3712 (21.06)
4836 (27.43)
7342 (41.65)

792 (10.70)
1557 (21.04)
1958 (26.46)
3098 (41.80)

22,270 (5.68)
55,505 (14.16)
104,836 (26.74)
209,444 (53.42)

1401 (7.95)
3226 (18.30)
5190 (29.45)
7808 (44.30)

633 (8.56)
1224 (16.54)
2066 (27.92)
3476 (46.98)

<0.001

145,618 (41.61)
162,245 (46.36)
42,114 (12.03)

2361 (14.27)
12,823 (77.49)
1365 (8.25)

2586 (36.14)
3716 (51.94)
853 (11.92)

<0.001

Received Radiation therapy

16,473 (4.21)

12,256 (69.33)

2350 (31.86)

<0.001

Underwent Surgery

368,260 (93.58)

5852 (33.08)

6217 (83.72)

<0.001

Received Systemic therapy

29,415 (7.53)

612 (3.47)

1628 (22.17)

<0.001

Insurance Status
Not insured
Private insurance
Medicaid
Medicare or other government insurance

<0.001

Education Level: Number of adults in
the patient’s zip code who did not
graduate from high school
>29% (level 1)
20–28.9% (level 2)
14–18.9% (level 3)
<14% (level 4)

<0.001

Socioeconomic Status: Median
household income for patient’s zip code
<40,227 (level 1)
40,227–50,353 (level 2)
50,354–63,332 (level 3)
>46,000 to >63,333 (level 4)
Treating Facility Type
Community cancer program
Academic/research program
Integrated Network Cancer Program
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Table 2. Histological subtypes of cutaneous melanoma (NCDB 2004–2015): mortality, lymph node status, and presence of
metastasis at diagnosis.
Melanoma,
not Otherwise
Specified
n (%)

Acral
Lentiginous
n (%)

Nodular
n (%)

Superficial
Spreading
n (%)

Lentigo
Maligna
n (%)

Others
n (%)

Died
(For all
cases)

Yes

57,076 (28.81)

1744 (33.9)

15,246 (41.58)

18,242 (15.65)

5203 (25.89)

5700 (33.2)

No

141,022 (71.19)

3400 (66.1)

21,422 (58.42)

98,329 (84.35)

14,896 (74.11)

11,470 (66.8)

Positive

23,344 (12.08)

1223 (23.89)

9547 (26.13)

8848 (7.61)

411 (2.05)

1804 (10.63)

Lymph node
status

Negative

77,179 (39.95)

2281 (44.55)

19,007 (52.03)

47,802 (41.12)

4699 (23.49)

9359 (55.14)

Unknown/Not
examined

92,655 (47.96)

1616 (31.56)

7977 (21.84)

59,596 (51.27)

14,891 (74.45)

5811 (34.23)

Present

16,532 (8.76)

97 (1.91)

1496 (4.18)

480 (0.42)

66 (0.33

821 (4.92)

34,269 (95.82)

114,905
(99.58)

19,728 (99.67)

15,872 (95.08)

ChiSquared
p-Value
<0.001

Metastasis
at Diagnosis

Absent

172,266 (91.24)

4971 (98.09)

<0.001

<0.001

Table 3. Characteristics of cutaneous melanoma based on race (NCDB 2004–2015): Ulceration, Breslow thickness, American
Joint Committee on Cancer (AJCC) clinical stage, and histology subtype.

Ulceration

Breslow
Thickness

AJCC Clinical
Stage

Histology
Subtype

Caucasians
n (%)

African Americans
n (%)

Others
n (%)

Absent

278,767 (81.72)

1125 (58.14)

5612 (81.23)

Present

62,341 (18.28)

810 (41.86)

1297 (18.77)

Total

341,108

1935

6909

<1 mm

199,529 (58.49)

680 (37.55)

4265 (61.38)

>1 to 2

68,282 (20.02)

309 (17.06)

1219 (17.54)

>2 to 4

41,798 (12.25)

346 (19.11)

804 (11.57)

>4

31,540 (9.25)

476 (26.28)

661 (9.51)

Total

341,149

1811

6949

1

173,291 (67.56)

471 (34.13)

3359 (67.31)

2

50,812 (19.81)

421 (30.51)

952 (19.08)

3

13,614 (5.31)

166 (12.03)

289 (5.79)

4

18,785 (7.32)

322 (23.33)

390 (7.82)

Total

256,502

1380

4990

Melanoma NOS

192,595 (50.23)

1355 (56.88)

4148 (52.47)

Acral Lentiginous

4395 (1.15)

465 (19.52)

284 (3.59)

Nodular

35,842 (9.35)

186 (7.81)

640 (8.1)

Superficial Spreading

114,225 (29.79)

222 (9.32)

2124 (26.87)

Lentigo Maligna

19,685 (5.13)

24 (1.01)

390 (4.93)

Others

16,720 (4.36)

130 (5.46)

320 (4.05)

Total

383,462

2382

7906

Chi-Squared
p-Value
<0.001

<0.001

<0.001

<0.001
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Table 4. Baseline characteristics of patients with ocular and mucosal melanoma (NCDB 2004–2015). H&N: head and neck;
GU: genitourinary; GIT: gastrointestinal tract excluding anorectum.
Noncutaneous Invasive
Melanoma (All Cases)

Ocular
n = 17,713 (%)

Head and
Neck
n = 2589 (%)

Genitourinary
n = 3255 (%)

Anorectal
n = 1351 (%)

Gastrointestinal
Tract, Excluding
Anorectum
n = 240 (%)

ChiSquared
p-Value

Females

8491 (47.94)

1299 (50.17)

3056 (93.89)

795 (58.85)

87 (36.25)

<0.001

423 (2.39)
9153 (51.67)
8137 (45.94)

28 (1.08)
899 (34.72)
1662 (64.19)

86 (2.64)
1167 (35.85)
2002 (61.51)

8 (0.59)
538 (39.82)
805 (59.59)

4 (1.67)
93 (38.75)
143 (59.58)

<0.001

Caucasian
AA

16,861 (95.19)
178 (1.00)

2307 (89.11)
149 (5.76)

2966 (91.12)
159 (4.88)

1191 (88.16)
61 (4.52)

217 (90.42)
11 (4.58)

Positive Lymph Nodes identified

18 (0.11)

259 (10.38)

597 (18.69)

299 (22.84)

56 (24.35)

<0.001

Metastasis present at diagnosis

326 (1.90)

338 (13.88)

230 (7.48)

233 (19.56)

72 (33.03)

<0.001

Age

≤30 Years
31 to 64 Years
≥65 Years
Race

<0.001

Died

5488 (30.98)

1806 (69.76)

1969 (60.49)

1003 (74.24)

169 (70.42)

<0.001

Received Radiation Therapy

12,256 (69.33)

1423 (55.37)

570 (17.64)

323 (24.14)

34 (14.35)

<0.001

Underwent Surgery

5852 (33.08)

2149 (83.10)

2849 (87.58)

1061 (78.77)

158 (65.83)

<0.001

Received Systemic therapy

612 (3.47)

520 (20.40)

576 (17.88)

460 (34.51)

72 (30.13)

<0.001

Disease burden between years 2004 and 2015 for invasive melanoma subtypes: As shown
in Figure 2 and Table S3, the total number of cases increased over the study period in all
three subtypes of melanoma. Trends in the proportion of patients diagnosed with metastasis at diagnosis did not appear to undergo significant changes.

Figure 2. Burden of invasive melanoma between the years 2004 and 2015.

Metastatic melanoma: Of all invasive melanoma cases, 20,691 (4.92%) were found to
have metastasis at presentation. Of these, the majority were of cutaneous origin (94.20%,
n = 19,492), followed by mucosal (4.22%, n = 873) and ocular (1.57%, n = 326). The mean
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age of patients with metastasis at diagnosis was 64.36 years for cutaneous cases versus
67.29 years for noncutaneous cases (t-test p-value < 0.001). The proportion of African
American (AA) patients amongst noncutaneous cases of metastatic melanoma was higher
(6.34%, n = 76) when compared to cutaneous (1.71%, n = 333) cases (p-value < 0.001).
Overall mortality was high amongst all subtypes (Table S4a,b). It was highest for mucosal
cases (87.51%), followed by ocular (85.28%) and cutaneous (80.04%) cases (p-value < 0.001).
3.2. Primary Outcome
Survival in patients with metastatic melanoma: Among those diagnosed with metastasis at presentation, median OS was 8.97 months for the cutaneous group, 9.10 months
for the ocular group, and 8.38 months for the mucosal group. As shown in Table 5 and
Figure 3A,B, the cutaneous group had better survival than both ocular and mucosal groups,
while no difference was noted between the survival of ocular vs. mucosal melanoma. To
give perspective, when we analyzed median OS for all cases, it was 161.12 months (about
13.5 years) in cutaneous melanoma, 122.91 months (about 10 years) in ocular melanoma,
and 26.29 months (about 2 years) in mucosal melanoma. Furthermore, when we specifically
analyzed nonmetastatic cases of cutaneous melanoma by stage, median OS was not reached
for Stage 1; it was 86.41 months (about 7 years) for Stage 2 and 61.37 months (about 5 years)
for Stage 3.

Figure 3. Kaplan–Meier analysis for (A) survival amongst all cases of invasive melanoma subtypes diagnosed between
2004 and 2015, (B) survival amongst melanoma cases with metastatic disease at presentation diagnosed between 2004 and
2015 by subtype, (C) survival pre- and postapproval of ipilimumab in 2011 amongst cases of cutaneous melanoma with
metastatic disease at presentation., (D) survival pre- and postapproval of ipilimumab in 2011 amongst cases of mucosal
melanoma with metastatic disease at presentation.
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Table 5. Survival analysis and comparison of median OS (overall survival) of melanoma cases with
metastatic disease at presentation (by subtype).
Survival Analysis

Cutaneous

Ocular

Mucosal

Median OS 2004–2010
Median OS 2011–2015
3-year survival 2004–2010
3-year survival 2011–2015
Comparison of Median OS
Cutaneous: 2011–2015 vs. 2004–2010
Ocular: 2011–2015 vs. 2004–2010
Mucosal: 2011–2015 vs. 2004–2010
Mucosal vs. Ocular
Ocular vs. Cutaneous
Mucosal vs. Cutaneous

8.11 months
10.35 months
14.64%
21.10%
Unadjusted HR
0.82
1.03
0.74
1.03
1.14
1.17

9.36 months
9.10 months
11.36%
11.88%
CI
0.79–0.85
0.81–1.31
0.65–0.86
0.90–1.18
1.01–1.28
1.09–1.26

7.36 months
10.71 months
5.53%
8.60%
p-value
<0.001
0.797
<0.001
0.645
0.029
<0.000

3.3. Secondary Outcomes
Impact of sociodemographic factors on odds of metastatic disease at diagnosis: Factors
analyzed included patient factors (age, race, sex, burden of comorbidities), melanoma type,
sociodemographic factors (education, income, insurance, geographical location), and hospital type. We first analyzed the above factors using a univariate logistic regression model. A
multivariate regression model was then developed by including the factors, which yielded
a p-value < 0.2 on univariate analysis (Table 6). Factors associated with higher odds of
presenting with metastatic disease at diagnosis included increasing age, male sex, and AA
race. While socioeconomic status had no association with this outcome, a rising level of
education correlated with progressively lower odds of presenting with metastatic disease.
Interestingly, patients being treated at community cancer programs had higher odds of
presenting with metastatic disease when compared to academic/research programs.
Impact of treatment facility type on mortality in patients with metastatic melanoma:
We analyzed the impact of treatment facility type on mortality amongst all cases of
metastatic melanoma using multivariate logistic regression analysis after adjusting for
melanoma type and other sociodemographic factors (Table S5). We noted that treatment
at an academic program was associated with lower mortality (OR 0.75, 95% CI 0.69–0.81,
p-value < 0.001) in contrast to a community cancer program. Table S2b analyzes the differences amongst the facilities in terms of the patients’ race, income, and level of education.
Overall survival after the approval of ICI for metastatic melanoma: We compared the
survival of patients who were metastatic at diagnosis, before and after the approval of
immunotherapy (2011 onwards) using the Cox proportional hazard model. The adjusted
hazards for survival in patients with metastatic melanoma after the introduction of ipilimumab (years 2011–2015) was 0.81 (95% CI 0.78–0.83, p-value < 0.001) when compared to
survival prior to its approval (years 2004–2010) (Table S6). Table 5 shows the median OS
and 3-year survival of metastatic cases for years 2004–2010 and 2011–2015. As shown in the
table, median OS during the years 2011–2015 versus 2004–2010 was significantly improved
in the cutaneous and mucosal groups. Kaplan–Meier survival curves for survival analysis
are shown in Figure 3C,D.
Impact of race upon survival in melanoma following ICI approval: To study the impact of race (in Caucasians and African Americans) on the survival benefit since the
approval of immunotherapy, we used multivariable Cox regression for the respective
cohorts. We adjusted for patient factors (age, race, sex, burden of comorbidities), melanoma
type, sociodemographic factors (education, income, insurance, geographical location), and
facility type (Tables S7 and S8). We noted a 20% improvement in survival for Caucasians
with the introduction of immunotherapy (adjusted HR 0.80, 95% CI 0.77–0.83, p < 0.001);
however, the difference did not reach statistical significance for African American patients
(adjusted HR 0.80, 95% CI 0.62–1.02, p-value = 0.073).
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Table 6. Multivariate logistic regression analysis for sociodemographic factors associated with the presence of metastasis at
diagnosis for cases of invasive melanoma.
Factors

OR

95% CI

p-Value

Age

1.01

1.00–1.01

<0.001

Female vs. Male

0.72

0.7–0.74

<0.001

Race
African Americans vs. Caucasians
Others vs. Caucasians

2.37
1.06

2.11–2.67
0.95–1.17

<0.001
0.313

Invasive melanoma subtype
Ocular vs. Cutaneous
Mucosal vs. Cutaneous

0.37
2.46

0.33–0.41
2.28–2.66

<0.001
<0.001

Charlson Deyo score
1 vs. 0
2 vs. 0
3 vs. 0

1.43
2.05
3.48

1.37–1.49
1.91–2.2
3.16–3.83

<0.001
<0.001
<0.001

Socioeconomic Status: Median household income for patient’s zip code
40,227–50,353 (level 2) vs. <40,227 (level 1)
50,354–63,332 (level 3) vs. <40,227 (level 1)
>46,000 to >63,333 (level 4) vs. <40,227 (level 1)

1.03
0.99
0.97

0.96–1.1
0.93–1.06
0.91–1.05

0.372
0.785
0.476

Number of adults in the patient’s zip code who did not graduate from high school
20–28.9% vs. >29%
14–18.9% vs. >29%
<14% vs. >29%

0.91
0.83
0.75

0.85–0.96
0.78–0.89
0.71–0.81

<0.001
<0.001
<0.001

Treating Facility Type
Academic/research program vs. Community cancer program
Integrated network cancer program vs. Community cancer program

0.76
1.01

0.74–0.79
0.97–1.06

<0.001
0.65

Insurance Status
Private insurance vs. Not insured
Medicaid vs. Not insured
Medicare or other government insurance vs. Not insured

0.35
1.26
0.44

0.32–0.37
1.15–1.39
0.4–0.47

<0.001
<0.001
<0.001

Geographical location
West vs. North East
Midwest vs. North East
South vs. North East

1.09
1.01
1.06

1.04–1.15
0.97–1.06
1.01–1.1

<0.001
0.53
0.01

4. Discussion
In this evaluation of real-world data, we present the results of a retrospective analysis
of the largest cohort of invasive melanoma cases (n = 419,773) diagnosed between 2004 and
2015. Cutaneous melanoma accounted for 93.80% of cases, followed by ocular (4.22%) and
then mucosal (2.00%) melanomas. The most common anatomic site of involvement in ocular
melanoma was the conjunctiva (90.28%), and in mucosal melanoma, the genitourinary tract
(43.78%). During this 10-year period of NCDB data collection, the number of cases increased
by 61.04% for cutaneous melanoma, by 39.27% for ocular melanoma, and by 59.07% for
mucosal melanoma. These findings are similar to those of other investigations, one of
which additionally concluded a doubling in melanoma incidence from 1982 to 2011 [13].
Notably, the proportion of those with metastatic disease at diagnosis did not change
drastically over the period of study. The nature of this dataset prevents us from making
definitive conclusions concerning the increasing incidence of melanoma. However, at least
from the standpoint of cutaneous melanoma, we can infer that majority of the patients
come from a population or generation that experienced a high degree of lifetime sunexposure and damage. This was prior to the widespread public adoption of skin cancer and
melanoma prevention strategies, particularly using FDA-regulated sunscreen protection
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products, which have been more often utilized in accordance with recommendations from
the American Academy of Dermatology (AAD).
There were notable differences among melanoma subtypes in terms of demographic
and socioeconomic factors. In our analysis, we found that both cutaneous and ocular
melanoma were frequently diagnosed at younger ages, in the subgroup aged 31–64 years
(51.33% and 51.67%, respectively), while mucosal melanoma patients were primarily
aged 65 years or older at diagnosis (62.03%). Patients with mucosal melanoma were
significantly more likely to be female (70.44% female), while in both cutaneous and ocular
melanoma, there was a slight male predominance. The higher proportion of females
in the mucosal melanoma subgroup is attributable to females accounting for 93.89% of
the most common subtype of mucosal melanoma, genitourinary melanoma. Of these,
90.48% were of vulvar or vaginal origin. More than half of the patients in the cutaneous
melanoma subgroup (52.53%) were privately insured, while 58.72% of patients in the
mucosal subgroup had Medicare or other government insurance. This may be attributable
to more patients being aged 65 or older in the mucosal melanoma subgroup. Patients
diagnosed with cutaneous melanoma had a higher level of education and resided in zip
codes with a higher median household income. It has been hypothesized that those with
less secondary education perceive themselves to be less likely to develop skin cancer [14].
Caucasians constituted an overwhelming majority of patients in all three groups (89.86–
97.39%). African Americans made up a significantly smaller proportion of patients in the
overall cohort, most notably comprising 0.6% of cutaneous melanoma cases. However, even
with lower incidence, their proportion was higher in noncutaneous melanoma, comprising
5.11% of mucosal melanomas.
There was considerable variation in the extent of disease (positive lymph nodes or
metastasis) between the groups at diagnosis, stratified by anatomic site. Positive lymph
nodes were identified at presentation in 11.64% of cutaneous and 16.76% of mucosal
melanoma patients but in only 0.11% of ocular melanoma cases. While sentinel lymph node
assessment is not standard of care in ocular melanoma, the low frequency of positive lymph
nodes in the ocular melanoma cohort could also be explained by the absence of lymphatic
supply in the uvea [15]. Metastatic disease was identified in 5.11% of cutaneous and 1.90%
of ocular melanoma patients and in 12.61% of mucosal melanoma cases. Notable factors
associated with lower odds of metastatic disease at presentation included female gender,
higher level of education, and lower burden of comorbidity. Interestingly, socioeconomic
factors did not seem to impact this outcome. Additionally, compared to community cancer
programs, academic/research cancer centers were 24% less likely to encounter cases that
were metastatic at diagnosis. This observation could possibly be explained by referral
bias and a higher index of suspicion coupled with better logistics in terms of diagnostic
capabilities and longitudinal follow-up at academic/research institutions.
The low rate of metastatic disease in ocular melanoma may be attributable to routine ocular examinations, leading to increased detection rates. About 30–40% of ocular
melanomas are asymptomatic and detected on a routine ocular examination [15]. Hidden
location, late onset of symptoms, potential amelanotic appearance, the presence of a rich
lymphovascular supply are some of the suspected causes that contribute to a delay in diagnosis and more advanced disease at presentation of mucosal melanoma [16,17]. Within the
mucosal melanoma group, the subtype with the highest proportion of metastatic disease
and positive lymph nodes at diagnosis included GIT (excluding anorectum) melanoma,
in which about one-third (33.03%) were metastatic and around one-fourth (24.35%) had
positive lymph nodes at diagnosis.
The odds of presenting with metastatic disease were higher in African Americans compared to Caucasians (OR 2.37; 95% CI 2.11–2.66, p < 0.001) after controlling for melanoma
type and sociodemographic factors. Metastatic disease was noted at presentation in 14.86%
of African American patients but in only 5.03% of Caucasians (chi-squared p-value < 0.001).
Our findings are similar to published literature, substantiating significantly higher odds
of African Americans having a more advanced stage at diagnosis [14]. Specifically, from
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the perspective of cutaneous melanoma, ulceration was present in 41.86% of AA patients
versus 18.28% Caucasians. Additionally, a Breslow depth of ≥4 mm was noted in 26.28% of
AA patients versus 9.25% Caucasians (Table 3). Some authors postulate (based on surveyed
African American patients) that this may relate to decreased awareness of susceptibility to
skin cancers in this population [14]. Moreover, there are differences in disease biology. For
example, acral lentiginous melanoma (ALM), which is typically associated with a more
aggressive course, is found in a greater proportion amongst African Americans compared
to Caucasians [18]. This was also observed in our analysis of cutaneous melanoma, where
19.52% of African Americans (while only 1.15% of Caucasians) had a histological diagnosis
of ALM (Table 3). The poorer prognosis of ALM is thought to be multifactorial, including differences in embryonic origin and immune microenvironment of glabrous versus
nonglabrous skin, differing mutational landscape (age-associated signatures, dominated
by chromosomal instability, instead of the more traditional UV-induced signatures), and
the difficulty of making an early diagnosis of ALM [19–21].
As expected, the therapeutic modalities utilized also varied based on the melanoma
subtype. The major therapeutic modality employed in patients with cutaneous and mucosal
melanoma was surgery (93.58% and 83.72%, respectively). Radiation therapy was most
often utilized in patients with ocular melanoma (69.33%). The frequency with which each
modality was utilized in our analysis is consistent with current practice guidelines [22,23].
The mucosal subgroup had the highest proportion of patients (22.17%) receiving systemic
therapy as a part of treatment (versus 3.47% and 7.53% in ocular and cutaneous melanoma,
respectively). This may be due to a higher proportion of metastatic cases at presentation
amongst mucosal melanoma. Within the mucosal cohort, the anorectal subtype had the
highest proportion of patients undergoing systemic therapy (34.51%). In addition to
the variation in type of treatment administered, the type of facility where the patients
received care also differed. While 41.61% of the cutaneous melanoma cases were treated
in community centers, the majority of cases of ocular (77.49%) and mucosal melanoma
(51.94%) received treatment at an academic/research institution, and we postulate this
reflects the unique, highly specialized care needs of these patients. Treatment at such centers
may have provided these patients with access to other immune checkpoint inhibitor-based
treatments through clinical trial enrollment. The abovementioned findings could, in part,
be the reason for a higher proportion of AA patients receiving care in academic centers
versus community centers (Table S2b)
Mortality greatly varied based on melanoma type and presence or absence of metastasis. The presence of metastasis was associated with a greater than 80% mortality across all
groups of melanomas (Table S4a,b). Amongst patients presenting with metastatic disease
at onset, the risk of death for those with metastatic mucosal melanoma was higher by
17% when compared to metastatic cutaneous melanoma. Similarly, the risk of death for
metastatic ocular melanoma was higher by 14% when compared to metastatic cutaneous
melanoma. This translated to a 3-year OS rate of 20.32% in the metastatic cutaneous
melanoma group versus 13.26% in metastatic ocular and 10.52% in metastatic mucosal
groups. There was no difference in survival of metastatic cases of mucosal versus ocular
melanoma. Using multivariate analysis, we examined the association of treatment facility
type on mortality of patients with metastatic melanoma and found that treatment at an
academic facility was associated with 25% lower mortality than in community cancer programs. This could possibly be explained by the lower odds of presenting with metastatic
disease (as was noted above), the availability of novel therapies within clinical trials, and
robust care logistics at academic/research institutions. Our investigation revealed a 20%
decrease in mortality for metastatic melanoma in the real-world setting following the
approval of immunotherapy (ICIs) in 2011. These findings are similar to clinical efficacies
reflected in the long-term survival follow-ups reported from the initial Phase 2 and Phase 3
clinical trials investigating ipilimumab. For example, ipilimumab was shown to produce a
survival of ≥2 years in 20% of pretreated patients [24]. We did not find a statistically significant improvement in survival following the introduction of ICIs amongst AA patients;
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this may be due to the small sample size of the AA patient cohort. When analyzed by
melanoma subtypes, the clinical benefit of ICI therapy was not noted within the metastatic
ocular melanoma subtype as well (HR 1.03, 95% CI 0.81–1.31, p-value = 0.797). Patients
with metastatic cutaneous and mucosal melanoma noted an improved survival of 18%
and 26%, and this translated to a median OS prolongation of 2.24 and 3.35 months, respectively. We postulate these differences could be due to variations in disease biology of the
melanoma subtypes.
There are several limitations of this study. These include its retrospective design, the
paucity of data in terms of the specifics of systemic therapy used, and molecular/genetic
characteristics. Though ipilimumab was the first ICI to be FDA approved in 2011 as
standard of care ICI for metastatic melanoma, a small cohort of metastatic melanoma
patients might have received other ICIs (e.g., nivolumab and pembrolizumab) through
clinical trial enrollment. Despite being a national database, NCDB may not be an accurate
representation of the entirety of melanoma cases, as only patients from participating
institutions are captured. As NCDB collects only absolute numbers of cases and is not
matched to local populations, cancer incidence rates cannot be measured with this data set.
Data regarding sentinel lymph node biopsy was not available for the pre-2012 years in the
database and hence not reported here. Mortality reported in NCDB is from all causes rather
than being cancer-specific, and this limits our ability to report disease-specific survival or
relative survival. Finally, NCDB does not provide data about recurrences and progression
of disease.
5. Conclusions
Metastatic melanoma continues to be a disease associated with high mortality. Its
rising incidence underlines the urgent need for cultivating a high degree of suspicion in
addition to improving our diagnostic capabilities. The disproportionately high odds of
metastatic disease amongst African Americans needs to be a priority for future research
and interventions, both medical and social. Our study substantiates a real-world survival
benefit in patients with metastatic melanoma since the approval of immunotherapy and
raises some important questions about differences in outcomes based on melanoma subtype.
Our findings also underscore the importance of ensuring uniform access to novel treatments
and furthering our understanding of molecular differences between melanoma subtypes
and amongst patients from different racial backgrounds.
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